New York, May 26, 2026, 07:03 (EDT)
Prenetics Global shares traded on Nasdaq are back in focus Tuesday after the holiday break. The stock ended Friday at $16.77, up 15% from its May 18 close of $14.54. According to company price data, PRE was up for three sessions in a row from May 20 to May 22.
U.S. equity markets reopened Tuesday after being closed Monday for Memorial Day. That set up trade to see if investors would stick with Prenetics’ move into IM8, the premium nutrition line co-founded with David Beckham. Nasdaq’s holiday calendar for 2026 also shows May 25 as a closed day.
Investors are linking the stock’s recent moves less to diagnostics and more to its consumer-health push. Last week, Prenetics brought in Jay Shetty as an IM8 global ambassador and shareholder, adding him as a non-sports name alongside Beckham, Giannis Antetokounmpo, Aryna Sabalenka, Ollie Bearman and Inter Miami CF.
Prenetics said in its announcement that IM8 is selling around 150,000 servings each day in 43 countries, with over 60% of sales coming from outside the U.S. May revenue looked close to $15.5 million, which hints at annualized recurring revenue of about $186 million, using the monthly run-rate.
Prenetics’ early Q1 numbers are out. The company put revenue at $36.0 million, with $33.8 million coming from IM8. Prenetics also lifted its 2026 IM8 revenue forecast to a range of $190 million to $210 million from its earlier $180 million to $200 million. Q2 revenue is expected at $46 million to $48 million.
IM8 saw close to six times year-on-year revenue growth for the quarter, CEO Danny Yeung said, calling the company’s run “extraordinary.” April monthly sales came in around $14.0 million and Yeung said May numbers looked stronger. Prenetics Global Limited
Prenetics is trying to back up its market pitch with more operating discipline. The company on May 14 named Brian J. Rosin as U.S. CFO of IM8, saying he will handle financial strategy, capital allocation, investor relations support and unit economics—how much profit or cash the unit gets per customer or order. Rosin said IM8’s “unit economics and retention” were notable in the field. Prenetics Global Limited
Prenetics is touting its capital moves. The company said it sold its entire digital-asset stake for $41.3 million and spent around $19 million on a $40 million share buyback already in progress. Buybacks cut the share count and can lift earnings per share, but take cash off the balance sheet.
Mixed take on competition. IM8 is going after nutrition and supplement spending worldwide but faces bigger, longer-running competitors. BellRing Brands puts its Premier Protein and Dymatize labels against IM8 in protein shakes and powders. Herbalife also says it has a stake in nutrition products like shakes, bars, vitamins, and sports hydration.
But there’s still execution risk. Prenetics warned its outlook comes from management’s own estimates, not a sure thing. The company listed risks: it might not keep the IM8 brand strong, or keep customers and creators engaged.
Prenetics posted a preliminary first-quarter adjusted EBITDA loss of $5.6 million, using a non-IFRS metric that removes interest, taxes, depreciation, amortization, and other items. The numbers are unaudited. The company noted that these kinds of adjustments can leave out items that could materially change reported results.
PRE faces a straightforward challenge this week: keep Friday’s close as investors look at IM8’s sales momentum but still aren’t sold on profits in a busy nutrition sector. That first post-holiday trade is likely to set the tone.
